



CURRICULUM VITAE of Ms. DANG LEI (danglei_hkbu@163.com)

Name: Dang Lei

Academic qualifications:

2007.09-2011.07 B. Sc Guang zhou University of Chinese Medicine, Guangzhou, China

2014.08-2016.06 M.Phil. Institute for Advancing Translational Medicine in Bone & Joint Diseases, Hong Kong Baptist University & Teaching Division, School of Chinese Medicine, Hong Kong Baptist University

Previous academic positions held:

2011.09-2012.11 Researcher Guangzhou General Pharmaceutical Research Institute

2012.11-2014.08 Research Assistant Institute for Advancing Translational Medicine in Bone & Joint Diseases, Hong Kong Baptist University & Teaching Division, School of Chinese Medicine, Hong Kong Baptist University

Present academic position:

2016.09- Ph.D. student Institute for Advancing Translational Medicine in Bone & Joint Diseases, Hong Kong Baptist University & Teaching Division, School of Chinese Medicine, Hong Kong Baptist University

Previous relevant research work:

Technical expertise Pharmacological Study, Pharmaceutical Sciences, Pharmaceutical Analysis, Pharmacokinetic, toxicokinetic

Research area Molecular understandings and RNAi-based & phytotherapy-based translational research in bone& Joints diseases.

Award

1. **Dang L**, Shaikh AB. Osteoblastic Plekho1 contributes to articular inflammation and bone repair failure in rheumatoid arthritis. The third prize. The National Competition – Hong Kong Regional Final – Hong Kong University Student Innovation and Entrepreneurship Competition 2017, 22-23 May, 2017. Hong Kong, China
2. **Dang L**, Liu J., Li D.F. A Delivery System Specifically Approaching Bone Resorption Surfaces to Facilitate Therapeutic Modulation of MicroRNAs in Osteoclasts. The second prize. "Entrepreneurship Challenge Cup" - China Competition - Hong Kong stage, 20-22 June, 2016, Hong Kong, China
3. **Dang L**, Guo B, Li D,...,Lu A, Zhang G. A Peptide-functionalized delivery system to target osteoclasts. ASBMR2014. Poster Presentation Abstract. Young Investigator Travel Grant Award. September 11-15, 2014.

Publication Records

1. Liu J., Li D.F., **Dang L. (co-author)**, ..., Lu A.P., Zhang G. Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer. *Sci Rep*. 2017 Jan; doi: 10.1038/srep40487.
2. Wang L.Y., Li F.F., **Dang L. (co-author)**, ..., Xu X.G., Lu A.P., Zhang G. *In Vivo* Delivery Systems for Therapeutic Genome Editing. *Int J Mol Sci*. 2016 April; doi:10.3390/ijms17050626.
3. Li D.F., Liu J., Guo B.S, Liang C., **Dang L.**, ..., Lu A.P., Zhang G. Osteoclast-derived exosomal miR-214-3p

inhibits osteoblastic bone formation. *Nat Commun.* 2016 March; doi: 10.1038/ncomms10872.

4. **Dang L. (co-author)**, Liu J., Li F.F., ... Lu A.P., Zhang G. Targeted Delivery Systems for Molecular Therapy in Skeletal Disorders. *Int J Mol Sci.* 2016 March; doi:10.3390/ijms17030428.
5. Jiang F., Liu B., Lu J., Li F.F., Li D.F., Liang C., **Dang L.**, ..., Lu A.P., Zhang G. Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems. *Int J Mol Sci.* 2015 Oct.; 16(10): 23784-822.
6. Liu J., **Dang L. (co-author)**, Li D.F., ... Lu A.P., Zhang G. A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of microRNAs in osteoclasts. *Biomaterials.* 2015 Feb; 52:148-160.
7. Liang C., Guo B.S., Wu H., Shao N., Li D., Liu J., **Dang L.**, ..., Zhang L., Lu A.P., Zhang G. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. *Nat Med.* 2015; 21(3):288-94.